News / Business
GUARDIAN TECHNOLOGIES INTERNATIONAL, INC. (OTCBB: GDTI); HEALTH DISCOVERY CORPORATION (OTCBB: HDVY); MIV THERAPEUTICS, INC. (OTCBB: MIVT); HOLMES BIOPHARMA, INC. (PINK SHEETS: HLMB)
Chat real-time with other investors about this GDTI news release, by clicking this link: http://www.stockwire.com/GDTI
GUARDIAN TECHNOLOGIES INTERNATIONAL, INC. (OTCBB: GDTI)
Guardian Technologies International, Inc. closed at $1.32 Friday, trading 296,469 shares
Company News- July 06, 2007: Guardian Technologies Announces Strategic Initiatives for 2007 Company Sets Course for Driving Shareholder Value Through Aggressive Commercialization of Products for Homeland Security and Healthcare Industries
Guardian Technologies International, Inc., innovators of groundbreaking threat detection technology with critical and immediate applications for the homeland security and healthcare markets, announced its Strategic Initiatives for fiscal 2007 and beyond. This announcement was made by William Donovan, President and Chief Operating Officer of Guardian Technologies International.
Guardian's strategy capitalizes on the increasing global demand for products and services that promote health and safety through cutting-edge threat detection technologies that enable x-ray scanners, medical MRIs and other advanced imaging technologies to not just "see" the contents of scanned objects, but to identify potential compound and physiological makeup. The Company's three-part, highly-focused plan consists of:
Significantly driving shareholder value through a high-margin, high-growth business model that capitalizes on market-disruptive technologies
Continue aggressive commercialization of next generation threat detection technology for global multibillion dollar homeland security markets
Continue aggressive development and commercialization of advanced disease detection technology for multibillion dollar healthcare and medical imaging markets
Mr. Donovan said, "Guardian has entered a new era with unprecedented opportunities for growth. We continue to see the results of our robust and highly-efficient commercialization strategy and follow through on our strategic goals. We strongly believe that the proprietary technology we have developed has immediate and profound applications and that over the next 12 to 24 months we will continue to gain new customers and ultimately solid revenues."
Strategic Initiative 1-Significantly drive shareholder value through a high-margin, high-growth business model that capitalizes on market-disruptive technologies
Guardian's overriding commitment to shareholder value has long been a tenet of the Company's overall corporate vision. To this end, the Company has identified a two year opportunity pipeline in excess of $150 million. Cooperative research and development agreements with the U.S. Department of Homeland Security and other key government and private agencies have already begun to move to the next stage. Additionally, limited new security technologies have been introduced into airport security checkpoint procedures since the 1980s, Guardian believes that the Company's next generation products are well positioned to fill that void.
Mr. Donovan said, "Guardian is firmly committed to doing everything in our power to build both immediate and long-term value for our shareholders. As our current investors have already seen, Guardian has a proven ability to execute its strategic business model."
Strategic Initiative 2-Continue aggressive commercialization of next generation threat detection technology for global multibillion dollar homeland security markets
Background: Guardian has developed and is currently opening up major international markets for its homeland security-focused PinPoint product. PinPoint enhances current-generation security x-ray scanners with the ability to autonomously determine the actual chemical composition of items viewed rather than relying on human operator vigilance and interpretation. Put simply, Guardian's technology can automatically alert security officers to the presence of explosives or other dangerous substances hidden in baggage. No other existing technology can do this.
This initiative has already seen substantial real-world market success, including:
June 29, 2007-Guardian announced the completion of its first commercial contract for PinPoint. The milestone contract was signed with a high-profile Russian security organization.
June 27, 2007-Guardian announced the successful completion of a milestone test that effectively accelerates the commercialization of PinPoint in the lucrative Russian market.
June 22, 2007-Guardian announced a milestone patent filing for its advanced threat detection technology. The patent wraps additional technological imaging advancements around its existing eleven patents.
Mr. Donovan said, "We are very excited about our recent developments in Russia in particular. We believe that once PinPoint is being actively used in real-world, high-pressure situations that we will be able to significantly accelerate our commercialization initiatives across other major markets around the globe."
Strategic Initiative 3-Continue aggressive development and commercialization of advanced disease detection technology for multibillion dollar healthcare and medical imaging markets Background: Existing medical imaging devices used in Computer Aided Detection (CAD) are further improved with Guardian's auto-diagnostic ability to detect anomalous tissue (e.g., tumors) and other potential disease states or conditions. This technology can detect tumors smaller than those a radiologist can see with the naked eye, enabling earlier treatment and potentially increasing survival rates.
This initiative has also already seen substantial real-world market success, including:
June 22, 2007-Guardian announced a milestone patent filing for its advanced threat detection technology. The patent wraps additional technological imaging advancements around its existing eleven patents.
April 26, 2007-Guardian signed a collaboration and strategic alliance agreement with Confirma, a market leader for CAD systems for breast MRIs.
April 3, 2007-Guardian announced that a recent clinical survey showed that employing the Company's Signature Mapping demonstrated its ability to detect and characterize tumors in screening mammograms.
Mr. Donovan said, "We are particularly excited about all of the milestones we have accomplished for healthcare industry product Signature Mapping. Not only do we believe that our product can potentially help save thousands of lives with earlier disease detections, we also believe that this market sector could be particularly valuable for our Company and for our investors."
Summary: Guardian optimizes the risk and reward profile of its business model by continuing to develop multiple revenue streams through targeting two multibillion dollar markets, the fast-growing homeland security industry and the vital healthcare industry. Managing risk is an important issue in our industries, and we are very careful never to over-expose our products, or to dilute our overall equity. Additionally, we believe that Guardian has positioned itself to enter this new era of growth at the right time, in the right markets and with the right products, which we believe is a testament to Guardian's compelling value proposition.
About Guardian Technologies International (OTCBB: GDTI)
The impact of Guardian's industry-first computer aided detection technologies are immediate and profound for helping to eliminate human error in both the Homeland Security and the Medical Industry sectors. The Company's software solutions can be seamlessly installed to complement existing imaging devices, such as baggage scanners and medical MRI, to scan the contents of any image and immediately identify items of interest not easily discernable by the human eye.
Airport Security: Guardian's technology complements and enhances current-generation baggage x-ray scanners with the ability to automatically and effectively detect, locate, and identify explosives and other types of threats.
Disease Identification: Existing medical imaging devices used in Computer Aided Detection (CAD) are further improved with Guardian's auto-diagnostic ability to detect anomalous tissue (e.g., tumors) and other potential disease states or conditions.
Technology-Independence: Because Guardian's technologies utilize and process the actual image output generated by the original imaging systems, virtually any existing or future imaging device can be upgraded with Guardian's products, delivering an instant, multi-billion dollar potential customer base with no competition.
Guardian's technology and product development partnerships include a Cooperative Research and Development Agreement (CRDA) with the U.S. Department of Homeland Security - Science and Technology Directorate. The Company's platform and product suite is protected by a robust patent portfolio. They are also ramping up new technologies and plan to acquire complementary technologies to accelerate the Company's high-growth business model.
Chat real-time with other investors about this HDVY news release, by clicking this link: http://www.stockwire.com/HDVY
HEALTH DISCOVERY CORPORATION (OTCBB: HDVY)
Health Discovery Corporation closed at $0.10 Friday, trading 142,116 shares
Company News- July 06, 2007: Health Discovery Corporation Settles Patent Infringement Suit against Ciphergen Biosystems, Inc., Ciphergen to License HDC's Support Vector Machine Technology
Health Discovery Corporation ("HDC") announced that its patent infringement action against Ciphergen Biosystems, Inc. has been settled. Under the terms of the agreement, Ciphergen will pay $600,000 to HDC and receive a non-exclusive license to use HDC's support vector machines in applications for Ciphergen's proprietary SELDI-based technologies. Ciphergen also dropped all counter-claims against HDC.
"This settlement is an excellent resolution for our company and shareholders," said Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "It is also the second favorable outcome in both of the patent infringement suits we've filed, adding credence and momentum to our ongoing licensing efforts. HDC remains firmly committed to monetizing our valuable intellectual property through close collaboration and development with our business partners, but we will also continue to protect our patent portfolio through robust enforcement action when necessary."
Savannah-based Health Discovery Corporation (OTCBB:HDVY) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery sm. The Company's SVM and RFE-SVM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.
About Health Discovery Corporation (OTCBB: HDVY)
Health Discovery Corporation operates as a biotechnology-oriented biomarker and pathway discovery company in the United States. It discovers a subset of genes that separates BPH from prostate cancer and BPH from normal; an AIDS gene set, which separates AIDS brain cells from nonAIDS brain cells; a subset of genes that indicates disease progression from less malignant to additional malignant forms of prostate cancer; and a set of leukemia genes, which separates ALL-T-cell leukemia from ALL-B-cell leukemia. The company also develops two imaging technologies, MammoSIGHT and MetastaSIGHT. Its pattern recognition technology is used in commercial markets, such as diagnostics, Internet search and spam, homeland security, financial futures, and other areas where analysis of data is required. The company was founded in 2001 as Direct Wireless Communications, Inc. and changed its name to Health Discovery Corporation in 2003. Health Discovery is based in Savannah, Georgia.
Chat real-time with other investors about this MIVT news release, by clicking this link: http://www.stockwire.com/MIVT
MIV THERAPEUTICS, INC. (OTCBB: MIVT)
MIV Therapeutics, Inc. closed at $0.63 Friday, trading 216,743 shares
Company News- July 06, 2007: MIV Therapeutics Inc. Announces Private Placement of Units
MIV Therapeutics, Inc., a developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced that it has entered into an agreement with various institutional investors for the unregistered private placement of an aggregate of 25,100,000 units at a price of $0.50 per unit for a total purchase price of $12.55 million, before deducting placement agent fees and offering expenses. Each unit consists of one share of common stock and one-half of one share purchase warrant exercisable at a price of $0.55 per share for a period of five years. The transaction is expected to close on or about July 10, 2007, subject to the satisfaction of certain customary closing conditions.
After deducting placement agent fees and offering expenses, MIV Therapeutics expects to receive net proceeds of approximately $11.7 million from the financing, which MIV Therapeutics intends to use to further the development of its novel drug eluting stents, commercial activities, and for general corporate purposes.
BMO Capital Markets Corp. acted as the sole placement agent for the offering.
The securities to be issued in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from the registration requirements of the Securities Act. The shares were offered and are being sold only to a limited number of institutional and accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the common stock, and the common stock issuable upon exercise of the warrants, issued in the private placement.
About MIV Therapeutics, Inc. (OTCBB: MIVT) MIV Therapeutics, Inc. is an advanced stage, research and development company pursuing the commercialization of the next generation of fully biocompatible coatings for stents and other medical devices with the intent of providing healing solutions for cardiovascular disease and other conditions. In collaboration with the University of British Columbia (UBC), the Company has developed unique coating technologies that utilize Hydroxyapatite (HAp) for application on medical devices and drug delivery systems. MIVT has a strategic alliance with the University of British Columbia (UBC), where it has licensed from the university worldwide rights to technologies for coating stents and other medical devices with HAp. This coating enhances the biocompatibility of implanted devices since it is a material that is found in the body as the main constituent of bone.
Chat real-time with other investors about this HLMB news release, by clicking this link: http://www.stockwire.com/HLMB
HOLMES BIOPHARMA, INC. (PINK SHEETS: HLMB)
Holmes Biopharma, Inc. closed at $1.75 Friday, trading 145,800 shares
Company News- July 05, 2007: Holmes Biopharma Appoints Associate Director of Clinical Operations
Holmes Biopharma, Inc. announced Mark Slama as new Associate Director of Clinical Operations for Qualia Clinical Services.
Mark holds a Bachelor of Arts from Concordia University, Nebraska and adds over 17 years of industry experience to Qualia and Holmes Biopharma's Management Team. Prior to joining Qualia, he had fulfilled several roles at MDS Pharma Services, a global clinical research company with over 4,000 employees. His vast experience includes such positions as, Clinical Science Manager, Clinical Research Associate, Study Coordinator and QC Technician.
"As Qualia continues to focus on developing a global presence, the addition of Mark to our Clinical Operations team provides significant industry experience further taking our Omaha operation to the next level of success," said Mr. John F. Metcalfe, President and CEO.
About Holmes Biopharma (PINK SHEETS: HLMB)
Holmes Biopharma, Inc. and its wholly owned subsidiary, Qualia Clinical Services, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services that help the pharmaceutical industry introduce new drug products rapidly from laboratory to the market. It currently has clinics in Omaha, Nebraska and Toronto, Canada. For more information about the company please visit our website at www.holmesbiopharma.com.
As the saying goes...follow the money!
To see the complete Movers & Shakers Blog go to: http://www.stockwire.com .
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
